Article Sidebar

Download
PDF
Statistic
Read Counter : 149 Download : 101

Downloads

Download data is not yet available.

Main Article Content

Abstract

This study was done to isolate and identify the non-O157 STEC in Karbala Province, Iraq. The results showed a new serotype of this bacteria (IQ1) showing different clinical symptoms such as fever, dehydration, colic, fatigue, nausea, abdominal cramps, nerves signs, renal failure, hemolytic uremic syndrome (HUS), hemolytic colitis, bloody to purulent diarrhea in human and animals infected by this pathogen. A total of 400 samples were collected from children’s stool and calves’ fecal samples, then cultured on different mediums for isolation. The biochemical tests were used for identification such as oxidase, citrate, urease and Voges–Proskauer, catalase, Methyl red, and indole tests. The PCR technique was used for the confirmation of the non-O157 STEC. The results showed from 197 calves’ samples 25 (12.69%) and from 203 children’s samples, 20 (9.85%) gave positive results. The antibiotic susceptibility test was used to know which antibiotic has the best results and the results revealed Ciprofloxacin with the best zone of inhibition compared with other antibiotics.

Keywords

Non-O157 STEC PCR Calves Human

Article Details

License
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The authors transfer the copyrights of their papers to the Iranian Society of Ichthyology. However, the information could be used in accordance with the Creative Commons licence (Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)

How to Cite
Abdullah, B. J. ., KADHIM, K. S., & AL-SHEMMARI, I. G. (2023). Isolation and identification of non-O157 Shiga toxin Escherichia coli from humans and calves using conventional and molecular technique. Iranian Journal of Ichthyology, 10(Special Issue 1), 172–180. Retrieved from https://www.ijichthyol.org/index.php/iji/article/view/937
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Barrett, S.P.; Savage, M.A.; Rebec, M.P.; Guyot, A.; Andrews, N. & Shrimpton, S.B. 1999. Antibiotic sensitivity of bacteria associated with community-acquired urinary tract infection in Britain. Journal of Antimicrobial Chemotherapy 44(3): 359-365.
  2. Becton Dickinson, 2013. Bula BD MacConkey Agar with Sorbitol. 4.
  3. Bharathi, M.J.; Ramakrishnan, R.; Maneksha, V.; Shivakumar, C.; Nithya, V. & Mittal, S. 2008. Comparative bacteriology of acute and chronic dacryocystitis. Eye 22(7): 953-960.
  4. Bharathi, M.J.; Ramakrishnan, R.; Vasu, S.; Meenakshi, R. & Palaniappan, R. 2002. In-vitro efficacy of antibacterials against bacterial isolates from corneal ulcers. Indian Journal of Ophthalmology 50(2): 109-114.
  5. Bielaszewska, M.; Mellmann, A.; Bletz, S.; Zhang, W.; Köck, R.; Kossow, A.; Prager, R.; Fruth, A.; Orth-Höller, D.; Marejková, M.; Morabito, S.; Caprioli, A.; Piérard, D.; Smith, G.; Jenkins, C.; Čurová, K. & Karch, H. 2013. Enterohemorrhagic Escherichia coli O26:H11/H−: a new virulent clone emerges in Europe. Clinical Infectious Diseases 56(10): 1373-1381.
  6. Briscoe, D.; Rubowitz, A. & Assia, E.I. 2005. Changing bacterial isolates and antibiotic sensitivities of purulent dacryocystitis. Orbit 24(1): 29-32.
  7. Chui, L.; Christianson, S.; Alexander, D.C.; Arseneau, V.; Bekal, S.; Berenger, B. & Ziebell, K. 2018. CPHLN recommendations for the laboratory detection of Shiga toxinproducing Escherichia coli (O157 and non-O157). Canada Communicable Disease Report= Releve des Maladies Transmissibles au Canada 44(11): 304-307.
  8. Dean, Z. 2013. Shiga toxin producing Escherichia coli (STEC) in cattle: factors affecting fecal shedding of E. coli O157:H7 and detection methods of non-O157 STEC. Dissertation, Department of Diagnostic Medicine/Pathobiology. Kansas State University.
  9. European Centre for Disease Prevention and Control. 2020. Shiga-toxin/verocytotoxin-producing Escherichia coli (STEC/VTEC) infection. ECDC annual epidemiological report for 2018. ECDC, Stockholm, Sweden.
  10. George, J. 2005. Thrombotic Thrombocytopenic purpura, and Haemolytic Uremic Syndrome. Current Hematological Reports 4:167-169.
  11. Getachew, T.; Asrat, D.; Yimtubezinash, W. & Messele, G. 2009. Microbiology of discharging ears in Ethiopia. Asian Pacific Journal of Tropical Medicine 2(1): 60-67.
  12. Gould, L.H.; Mody, R.K.; Ong, K.L.; Clogher, P.; Cronquist, A.B.; Garman, K.N. & Griffin, for the Emerging Infections Program FoodNet Working Group, P.M. 2013. Increased recognition of non-O157 Shiga toxin–producing Escherichia coli infections in the United States during 2000–2010: epidemiologic features and comparison with E. coli O157 infections. Foodborne Pathogens and Disease 10(5): 453-460.
  13. Gyles, C.L. 2006. Shiga toxin-producing Escherichia coli: a review. Journal of Animal Science 85: 45-62.
  14. Gyles, C.L. 2007. Shiga toxin-producing Escherichia coli: an overview. Journal of Animal Science 85: 45-62.
  15. Hirvonen, J.J.; Siitonen, A. & Kaukoranta, S.S. 2012. Usability and performance of CHROMagar STEC medium in detection of Shiga toxin-producing Escherichia coli strains. Journal of clinical microbiology, 50(11), 3586-3590
  16. Hussein, H.S. & Bollinger, L.M. 2008. Influence of selective media on successful detection of Shiga toxin–producing Escherichia coli in food, fecal, and environmental samples. Foodborne Pathogens and Disease 5(3): 227-244.
  17. Iqbal, M.K. & Patel, I.K. 2002. Susceptibility patterns of Escherichia coli: Prevalence of multidrug-resistant isolates and extended spectrum beta-Lactamase phenotype. The Journal of the Pakistan Medical Association 52: 407-417.
  18. Johnson, K.E.; Thorpe, C.M. & Sears, CL. 2006. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. Clinical Infectious Diseases 43: 1587-1595.
  19. Karlowsky, J.A.; Kelly, L.J.; Thornsberry, C.; Jones, M.E. & Sahm, D.F. 2002. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrobial Agents and Chemotherapy 46(8): 2540-2545.
  20. Karmali, M.A.; Petric, M.; Lim, C., Fleming, P.C.; Arbus, G.S. & Lior, H. 2004. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. The Journal of Infectious Diseases 189(3): 556-63
  21. Khan, N.A.; Saba, N.; Abdus, S. & Ali, A.Q. 2002. Incidence and antibiogram patterns of E. coli isolates from various clinical samples from patients at NIH Islamabad. Pakistan Journal of Biological Sciences 1: 111-113.
  22. Leininger, D.J.; Roberson, J.R. & Elvinger, F. 2001. Use of eosin methylene blue agar to differentiate Escherichia coli from other gram-negative mastitis pathogens. Journal of Veterinary Diagnostic Investigation 13(3): 273-275.
  23. Mac, F.J.F. 1980. Biochemical Tests for Identification of Medical Bacteria. pp: 173-183. Baltimore: Williams and Wilkins Co.
  24. Mulu, A.; Moges, F.; Tessema, B. & Kassu, A. 2006. Pattern and multiple drug resistance of bacterial pathogens isolated from wound infection at University of Gondar Teaching Hospital, Northwest Ethiopia. Ethiopian Medical Journal 44(2): 125-131.
  25. Nataro, J.P. & Kaper, J.B. 1998. Diarrheagenic E. coli. Clinical Microbiology Reviews 11(1): 142-201.
  26. Novicki, T.J.; Daly, J.A.; Mottice, S.L. & Carroll, K.C. 2000. Comparison of sorbitol MacConkey agar and a two-step method which utilizes enzyme-linked immunosorbent assay toxin testing and a chromogenic agar to detect and isolate enterohemorrhagic Escherichia coli. Journal of Clinical Microbiology 38(2): 547-551.
  27. Okonko, I.O.; Soleye, F.A.; Amusan, T.A.; Ogun, A.A.; Ogunnusi, T.A.; Ejembi, J. & Onajobi, B.I. 2009. Incidence of multi-drug resistance (MDR) organisms in Abeokuta, Southwestern Nigeria. Global Journal of Pharmacology 3(2): 69-80.
  28. Orrett, F.A. & Shurlandl, S.M. 2001. Prevalence of Resistance to Antimicrobials of Escherichia coli Isolates fTrom Clinical Sources at a Private Hospital in Trinidad. Japanese Journal of Infectious Diseases 54: 64-68.
  29. Parry, S.M. & Palmer, S.R. 2000. The public health significance of VTEC O157. Symposium series (Society for Applied Microbiology) 88(Suppl): S1-S9.
  30. Parsons, B.D.; Zelyas, N.; Berenger, B.M. & Chui, L. 2016. Detection, characterization, and typing of Shiga toxin-producing Escherichia coli. Frontiers in Microbiology 7: 478.
  31. Petkovšek, Z.; Eleršič, K.; Gubina, M.; Zgur-Bertok, D. & Starčič Erjavec, M. 2009. Virulence potential of Escherichia coli isolates from skin and soft tissue infections. Journal of Clinical Microbiology 47(6): 1811-1817.
  32. Quinn, P.J.; Carter, M.E.; Markey, B. & Carter, G.R. 2004. Clinical Veterinary Microbiology. Mosby Edinburgh, London, New York, Oxord and Philadephia. USA. pp: 21- 63
  33. Rawaa Sadi, A. 2021. Comparative Treatment Study among Colicin E1 EnterocinA1 and Enrofloxacin of Non-O157 Shiga Toxin-Producing E. coli Experimentally in Rabbits That Isolated from Children and Dogs. University of Baghdad.
  34. Sami Jarad, A. 2016. Bacteriological, Immunological and Pathological Study on Mice Experimentally Infected with NonO157 Shiga Toxin Producing E.coli Isolated from Children and Calves. Baghdad University
  35. Serna IV, A. & Boedeker, E.C. 2008. Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections. Current opinion in gastroenterology 24(1): 38-47.
  36. Slutsker, L.; Ries, A.A.; Greene, K.D.; Wells, J.G.; Hutwagner, L. & Griffin, P.M. 1997. Escherichia coli O157: H7 diarrhea in the United States: clinical and epidemiologic features. Annals of Internal Medicine 126(7): 505-513.
  37. Tenaillon, O.; Skurnik, D.; Picard, B. & Denamur, E. 2010. The population genetics of commensal Escherichia coli. Nature Reviews Microbiology 8(3): 207-217.
  38. Todar, K. 2007. Pathogenic E.coli. online textbook of bacteriology. University of Wisconsin-Madison, Department of Bacteriology, pp: 11- 30.
  39. Torres, A.G.; Knack, K.J.; Tutt, C.B.; Popov, V. & Kaper, J.B. 2004. Characterization of the second long polar (LP) fimbriae of Escherichia coli O157:H7 and distribution of LP fimbriae in other pathogenic E. coli strains. FEMS Microbiology Letters 238(2): 333-344.
  40. Valilis, E.; Ramsey, A.; Sidiq, S. & DuPont, H.L. 2018. Non-O157 Shiga toxin-producing Escherichia coli-a poorly appreciated enteric pathogen: systematic review. International Journal of Infectious Diseases 76: 82-87.
  41. Vishram, B.; Jenkins, C.; Greig, D.R.; Godbole, G.; Carroll, K.; Balasegaram, S. & Byrne, L. 2021. The emerging importance of Shiga toxin-producing Escherichia coli other than serogroup O157 in England. Journal of Medical Microbiology 70(7).
  42. Wanger, A.; Chavez, V.; Huang, R.; Wahed, A.; Dasgupta, A. & Actor, J. K. 2017. Microbiology and molecular diagnosis in pathology: a comprehensive review for board preparation, certification and clinical practice. Elsevier Science Publishing Co Inc. USA
  43. Wariso, B.A. & Ibe, S.N. 2006. Bacteriology of chronic discharging ears in Port Harcourt, Nigeria. West African Journal of Medicine 25(3): 219-222.
  44. William, S. 2007. Haemolytic Uremic Syndrome H.U.S., American Academy of Emergency Medicine 54: 664-669.
  45. Xavier, P.D.; Vijay, S.T.; Ramya, V.; Frankantony, P.B.; Priyanka, K.S. & Shiny, J. 2016. Metachromasia and Metachromatic Dyes: A review. International Journal of Advanced Health Sciences 2: 14-20.
  46. Zhanel, G.G.; Hisanaga, T.L.; Laing, N.M.; DeCorby, M.R.; Nichol, K.A.; Weshnoweski, B. & NAUTICA, Group. 2006. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). International Journal of Antimicrobial Agents 27(6): 468-475.